Nurse-Led PTSD Treatment in Primary Care
A Hybrid Implementation-Effectiveness Trial of Nurse-Delivered Post-Traumatic Stress Disorder Treatment in Primary Care
1 other identifier
interventional
100
1 country
2
Brief Summary
Purpose of the Study Post-traumatic stress disorder (PTSD) is a common and serious condition, but many people cannot get the help they need because there are not enough mental health specialists (like psychologists or psychiatrists) available. This study is testing a new program called NurseNET. The goal of NurseNET is to train nurses to provide a proven, short-term trauma treatment called Narrative Exposure Therapy (NET). Why This Study is Important Most people see their nurse or doctor for health concerns. Because nurses are highly trusted and already work on the front lines of healthcare, they may be in the best position to offer PTSD treatment quickly and conveniently. This study aims to see if nurse-led care can bridge the gap between patients and the treatment they deserve. What the Study Involves Researchers will enroll 100 participants who have symptoms of PTSD. Participants will work with a trained nurse in a primary care setting to complete the NurseNET program. The Treatment: The program consists of 4 to 6 sessions. During these sessions, the nurse helps the patient talk through their life story and process difficult memories in a safe, supportive way. What We Are Measuring: The research team will look at several factors to see if the program is successful: Effectiveness: Do PTSD symptoms improve after working with the nurse? Feasibility and Acceptability: Do patients and nurses find this type of care easy to use and helpful? Health Impact: Since PTSD is linked to heart health, the study will also look at whether the treatment improves things like blood pressure or physical activity levels. Goal of the Research By the end of this study, researchers hope to show that nurses can safely and effectively provide trauma care. If successful, this model could be used across the United States to make PTSD treatment much easier to access for everyone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2026
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 18, 2026
CompletedFirst Posted
Study publicly available on registry
February 24, 2026
CompletedStudy Start
First participant enrolled
March 30, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2029
April 29, 2026
April 1, 2026
2.2 years
February 18, 2026
April 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
PTSD Checklist for DSM-5 (PCL-5)
20-item self-report scale that assesses the 20 DSM-5 PTSD symptoms; used to monitor symptom change/screen for probable PTSD diagnosis.
Baseline, 3, 6, 12 months
Secondary Outcomes (10)
Patient Health Questionnaire (PHQ-9)
Baseline, 3, 6, 12 months
Generalized Anxiety Disorder (GAD-7)
Baseline, 3, 6, 12 months
Somatic Symptoms Scale (SSS-8)
Baseline, 3, 6, 12 months
Medication Adherence Report Scale (MARS-5)
Baseline, 3, 6, 12 months
Self-Efficacy for Managing Chronic Conditions (PROMIS)
Baseline, 3, 6, 12 months
- +5 more secondary outcomes
Study Arms (2)
NurseNET
EXPERIMENTALThe NurseNET experimental arm involves training primary care nurses to deliver a condensed, 4 session version of Narrative Exposure Therapy (NET) to patients with PTSD symptoms. This task sharing approach integrates evidence-based trauma treatment directly into the primary care workflow to increase service access and improve select health outcomes.
Minimally-Enhanced Usual Care
ACTIVE COMPARATORThe minimally-enhanced usual care arm consists of provision of psychoeducational materials regarding trauma symptoms and available community resources, followed by referral to PTSD treatment. This arm serves as a rigorous control to account for the effects of time and general medical attention while identifying the specific clinical impact of the nurse-led Narrative Exposure Therapy intervention.
Interventions
NurseNET is a pragmatic clinical intervention designed to deliver evidence-based PTSD treatment within primary care workflows. It is distinguished from traditional Narrative Exposure Therapy (NET) and other primary care behavioral health interventions by the following four core elements: Nurse-Led Task Sharing. Unlike traditional models that rely on licensed mental health specialists (psychologists or social workers), NurseNET is delivered entirely by nurses. This leverages the existing nursing workforce to bypass specialist shortages and reduce the "referral cliff" associated with external mental health consultations. Dose-Compressed Protocol. While standard NET often extends to 10 or more sessions, NurseNET utilizes a condensed 4-session format. This "minimum therapeutic dose" is specifically engineered for the high-throughput U.S. healthcare environment. We use a safety-net supervision framework and leverage the holistic nurse preparation in the context of co-located/integrated care
Standard referral to PTSD treatment.
Eligibility Criteria
You may qualify if:
- o PTSD + trauma exposure (PCL-5 score ≥28, plus trauma endorsed on LEC-5/CAPS)
- Life-threatening CV event in the last 90 days (including myocardial infarction/heart attack, acute cerebrovascular accident/stroke, sudden cardiac arrest, acute decompensated heart failure, or life-threatening arrhythmia requiring cardioversion or defibrillation).
- Primary care patient at Rush University Medical Center
You may not qualify if:
- o Safety risk (documented suicidal ideation/need for acute psychiatric care)
- NET conflict (actively receiving psychotherapy/PTSD treatment)
- Cognitive/decisional non-capacity (University of California, San Diego Brief Assessment of Capacity to Consent \[UBACC\] ≤ 14.5)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Rush University Medical Center
Chicago, Illinois, 60612, United States
Rush University Medical Center
Brookfield, Wisconsin, 53045, United States
Related Publications (2)
Dickins KA. Improving Traumatic Stress with Justice-Impacted Women and Women Experiencing Homelessness: A Pilot Study of Narrative Exposure Therapy. Issues Ment Health Nurs. 2024 Feb;45(2):121-141. doi: 10.1080/01612840.2023.2238091. Epub 2023 Aug 24.
PMID: 37616593BACKGROUNDDickins KA, Houlihan MC, Neely S, Smith DL, Nowell H, Karnik N, Held P. Improving post-traumatic stress symptoms in homeless-experienced women using narrative exposure therapy: a single-arm, open pilot study. Eur J Psychotraumatol. 2026 Dec;17(1):2620215. doi: 10.1080/20008066.2026.2620215. Epub 2026 Feb 6.
PMID: 41645787BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
February 18, 2026
First Posted
February 24, 2026
Study Start
March 30, 2026
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
September 1, 2029
Last Updated
April 29, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Individual Participant Data (IPD) will not be shared to ensure the maximum protection of participant privacy and confidentiality, which is paramount given the highly sensitive nature of the traumatic life events disclosed during Narrative Exposure Therapy. Due to the narrative nature of the intervention, the risk of deductive re-identification remains high even in de-identified datasets in this early, small sample pilot trial.